Maa: Yhdysvallat
Kieli: englanti
Lähde: NLM (National Library of Medicine)
METOPROLOL SUCCINATE (UNII: TH25PD4CCB) (METOPROLOL - UNII:GEB06NHM23)
NCS HealthCare of KY, Inc dba Vangard Labs
METOPROLOL SUCCINATE
METOPROLOL TARTRATE 25 mg
ORAL
PRESCRIPTION DRUG
Metoprolol succinate is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including metoprolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with differe
Tablets containing metoprolol succinate equivalent to the indicated weight of metoprolol tartrate, USP, are white, biconvex, film-coated, and scored. Tablet Shape Engraving Blistercards of 30 NDC 0615- Blistercards of 15 NDC 0615- Blistercards of 14 NDC 0615- Unit dose boxes of 30 NDC 0615- 25 mg Oval A/β 8024-39 8024-05 8024-14 8024-30 50 mg Round A/mo 8025-39 8025-05 8025-14 100 mg Round A/ms 200 mg Oval A/my Store at 25°C (77°F). Excursions permitted to 15-30°C (59- 86°F). (See USP Controlled Room Temperature.)
New Drug Application Authorized Generic
METOPROLOL SUCCINATE- METOPROLOL SUCCINATE TABLET, EXTENDED RELEASE NCS HEALTHCARE OF KY, INC DBA VANGARD LABS ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE METOPROLOL SUCCINATE SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR METOPROLOL SUCCINATE. METOPROLOL SUCCINATE TABLET, EXTENDED-RELEASE FOR ORAL USE INITIAL U.S. APPROVAL: 2006 WARNING: ISCHEMIC HEART DISEASE _(SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING)_ FOLLOWING ABRUPT CESSATION OF THERAPY WITH BETA-BLOCKING AGENTS, EXACERBATIONS OF ANGINA PECTORIS AND MYOCARDIAL INFARCTION HAVE OCCURRED. WARN PATIENTS AGAINST INTERRUPTION OR DISCONTINUATION OF THERAPY WITHOUT THE PHYSICIAN’S ADVICE. (5.1) INDICATIONS AND USAGE Metoprolol Succinate is a beta -selective adrenoceptor blocking agent. Metoprolol Succinate is indicated for the treatment of: Hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. (1.1) Angina Pectoris. (1.2) Heart Failure - for the treatment of stable, symptomatic (NYHA Class II or III) heart failure of ischemic, hypertensive, or cardiomyopathic origin. (1.3) DOSAGE AND ADMINISTRATION Administer once daily. Dosing of metoprolol succinate should be individualized. (2) Heart Failure: Recommended starting dose is 12.5 mg or 25 mg doubled every two weeks to the highest dose tolerated or up to 200 mg. (2.3) Hypertension: Usual initial dosage is 25 to 100 mg once daily. The dosage may be increased at weekly (or longer) intervals until optimum blood pressure reduction is achieved. Dosages above 400 mg per day have not been studied. (2.1) Angina Pectoris: Usual initial dosage is 100 mg once daily. Gradually increase the dosage at weekly intervals until optimum clinical response has been obtained or there is an unacceptable bradycardia. Dosages above 400 mg per day have not been studied. (2.2) Switching from immediate-release metoprolol to Lue koko asiakirja